HTG Nets First Tranche of $15.7M Series D
HTG Inc., a developer of molecular technology, has closed the first tranche of a $15.7 million Series D round led by new investor Novo A/S. Fletcher Spaght Ventures also joined the round with existing shareholders Merck Capital Ventures, Solstice Capital and Valley Ventures. The money will help HTG market its multi-plex gene expression testing platform, the company said. HTG is based in Tucson, Arizona.
24 February 2011•3 mins read
